Amendments to the Specification

Please amend the specification under the provisions of 37 C.F.R. § 1.121(b)(1) as follows:

Please replace the paragraph at page 13, lines 13-24, of the specification with the following amended paragraph:

Modafinil may also be administered to an individual in conjunction with a dopaminergic agent. Preferably, when administered, the dopaminergic agent crosses the blood-brain barrier. A variety of dopaminergic agents are known that may be administered in conjunction with modafinil according to the invention, including, without limitation, apomorphine, bromocriptine, amantadine, pergolide, pramipexole, ropinirole, fenoldopam, cabergoline, rotigotine, lysuride, talipexale, 7-OH DPAT, quinpirole, SKF-38393, L-dopa (levadopa), or combinations thereof. In fact, it has been discovered that the high potency dopamine agonist apomorphine or high doses of the dopamine precursor L-dopa are particularly effective at treating impaired neurological function, including emergence from coma and other altered consciousness states, in individuals who have sustained a brain injury (see, commonly owned, co-filed, international application No. PCT/US2004/008120 (Atty. Docket No. NEU-101.1 PCT)) ~~international application No. PCT/US04/_____; [Atty. Docket No. NEU-101.1 PCT)~~.